LEXINGTON, Mass.--(BUSINESS WIRE)--Nov. 7, 2012--
Synta Pharmaceuticals Corp. (NASDAQ: SNTA) announced today that interim
results from the Phase 2b/3 GALAXY trial will be presented at the
Chemotherapy Foundation Symposium in New York City on Friday, November 9
during the 11:45 a.m. session on new agents for lung cancer. Presenting
this data at the conference will be Dr. Suresh Ramalingham, Professor,
Hematology & Medical Oncology, and Director, Translational Thoracic
Malignancies Program, of the Winship Cancer Institute of Emory
University.
The GALAXY trial is a Phase 2b/3 program designed to compare single
agent docetaxel versus docetaxel plus ganetespib, a potent and selective
Hsp90 inhibitor, as second-line treatment of advanced non-small cell
lung cancer. The presentation will review prior results highlighted at
the 2012 Congress of the European Society for Medical Oncology (ESMO)
last September.
About Ganetespib
Ganetespib is a potent inhibitor of heat shock protein 90 (Hsp90) that
is structurally unrelated to first-generation, ansamycin-related Hsp90
inhibitors. In preclinical experiments, ganetespib has shown activity in
multiple tumor models both as a single agent and in combination with
certain widely used cancer agents. Company-sponsored clinical trials
with ganetespib include 1) the GALAXY Phase 2b/3 trial evaluating
ganetespib in combination with docetaxel as second-line treatment of
non-small cell lung cancer (NSCLC), 2) the CHIARA Phase 2 trial
evaluating ganetespib monotherapy in ALK+ NSCLC, and 3) the ENCHANT
Phase 2 trial evaluating ganetespib as first-line treatment for HER2+
and triple-negative metastatic breast cancer. In addition, ganetespib is
being evaluated in investigator-sponsored trials including lung, breast,
prostate, gastric, pancreatic, and colorectal cancers as well as ocular
melanoma, acute myeloid leukemia and multiple myeloma. Information on
these trials can be found at www.clinicaltrials.gov.
About the GALAXY Trials™
The GALAXY (Ganetespib Assessment in Lung cAncer
with docetaXel) program consists of two randomized trials
comparing the combination of ganetespib and docetaxel versus docetaxel
alone in patients with Stage IIIB/IV NSCLC who have received one prior
systemic therapy: a Phase 2b study to determine the patient population
most likely to derive benefit from ganetespib, and a Phase 3 pivotal
trial enriched for this identified population, More information about
the GALAXY trials can be found at www.clinicaltrials.gov
(NCT01348126).
About Hsp90
Hsp90 is a molecular chaperone required for the proper folding and
activation of many cancer-promoting proteins, and is recognized as a key
facilitator of cancer cell growth and survival. Many of the “client
proteins” of Hsp90 – such as ALK, AKT, BCR-ABL, BRAF, KIT, MET, EGFR,
FLT3, HER2, HIF-1alpha, PDGFRA, VEGFR are the targets of clinically
validated cancer drugs. In preclinical studies, inhibiting Hsp90 causes
the degradation of multiple client proteins and leads to cancer cell
death.
About Synta Pharmaceuticals
Synta Pharmaceuticals Corp. is a biopharmaceutical company focused on
discovering, developing, and commercializing small molecule drugs to
extend and enhance the lives of patients with severe medical conditions,
including cancer and chronic inflammatory diseases. Synta has a unique
chemical compound library, an integrated discovery engine, and a diverse
pipeline of clinical- and preclinical-stage drug candidates with
distinct mechanisms of action and novel chemical structures. All Synta
drug candidates were invented by Synta scientists using our compound
library and discovery capabilities. For more information, please visit www.syntapharma.com.
Safe Harbor Statement
This media release contains forward-looking statements about Synta
Pharmaceuticals Corp. Such forward-looking statements can be identified
by the use of forward-looking terminology such as "will", "would",
"should", "expects", "anticipates", "intends", "plans", "believes",
"may", "estimates", "predicts", "projects", or similar expressions
intended to identify forward-looking statements. Such statements,
including statements relating to the timing, developments and progress
of our GALAXY trial, our clinical development plans for ganetespib and
the anticipated design of the Phase 3 portion of the GALAXY trial,
reflect our current views with respect to future events and are based on
assumptions and subject to risks and uncertainties that could cause
actual results to differ materially from those expressed or implied by
such forward-looking statements. Those risks and uncertainties include
whether the results from the interim analysis of the Phase 2b portion of
the GALAXY trial will be consistent with future data from the Phase 2b
portion and the Phase 3 stage of the trial; whether the results at the
conclusion of the Phase 2b portion of the trial will demonstrate safety
and statistically significant efficacy; challenges with respect to
patient enrollment or other delays in our clinical development plans; as
well as other risks and uncertainties described in the "Risk Factors"
section of our Form 10-K for the year ended December 31, 2011, as filed
with the Securities and Exchange Commission, including those under the
heading “Risks Related to the Development and Regulatory Approval of our
Drug Candidates.” Synta undertakes no obligation to publicly update
forward-looking statements, whether because of new information, future
events or otherwise, except as required by law.
Source: Synta Pharmaceuticals Corp.
Investor Relations:
Synta Pharmaceuticals Corp.
George
Farmer, 781-541-7125
[email protected]